Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hybio Pharmaceutical Licenses Semaglutide to Vitamedic for Brazil Market

Fineline Cube Jan 11, 2026
Company Deals

Merck in Talks to Acquire Revolution Medicines for $28‑32 Billion in Oncology Push

Fineline Cube Jan 11, 2026
Company Deals

Takeda Licenses Halozyme’s ENHANZE Technology for Vedolizumab in Global Deal

Fineline Cube Jan 11, 2026
Company Deals

Eisai China and Xuanwu Hospital Forge Strategic Cooperation for Drug R&D

Fineline Cube Jan 11, 2026
Company Deals

InduPro Partners with Lilly on $950M Oncology Deal Using Proximity-Guided Platform

Fineline Cube Jan 10, 2026
Policy / Regulatory

NMPA Issues New Rules to Strengthen Pharmaceutical Contract Manufacturing Oversight

Fineline Cube Jan 9, 2026
Company Drug

Genrix Bio’s GR1803 NDA Accepted for BCMA-Targeted Multiple Myeloma Therapy

Fineline Cube Jan 11, 2026
Company Drug

RemeGen’s RC48 Wins Fourth Breakthrough Therapy Designation for Gastric Cancer Combo

Fineline Cube Jan 11, 2026
Company Deals

Boehringer Ingelheim Pledges USD 5 Million to WHO Foundation for Global Healthcare Advancement

Fineline Cube Oct 16, 2024

Boehringer Ingelheim (BI), a leading German pharmaceutical company, has joined forces with the World Health...

Company

J&J Reports Q3 2024 Revenue Growth, Raises Full-Year Guidance on Strong Pipeline Progress

Fineline Cube Oct 16, 2024

Johnson & Johnson (J&J, NYSE: JNJ) has released its financial report for the third quarter...

Company Drug

Shanghai Junshi Biosciences’ Toripalimab Wins Marketing Approvals in India and Hong Kong for Nasopharyngeal Carcinoma

Fineline Cube Oct 16, 2024

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180), a leading biotech company based in...

Company

Eli Lilly Launches Medical Innovation Center and Gateway Labs in Beijing to Accelerate Clinical Trials and R&D

Fineline Cube Oct 16, 2024

Eli Lilly & Co. (NYSE: LLY), a leading pharmaceutical corporation in the US, has announced...

Company Drug

Jiangsu Hengrui Resubmits Application for Camrelizumab Combo in HCC to FDA

Fineline Cube Oct 16, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a prominent pharmaceutical company based in China, has...

Company Drug

Innovec Biotherapeutics’ IVB103 Gene Therapy for nAMD Receives Clinical Trial Approval from China’s CDE

Fineline Cube Oct 16, 2024

Beijing InnoVec Biotherapeutics Inc., a leading gene therapy company based in China, has announced that...

Company Drug

Aficamten Market Filing Accepted by China’s CDE for Hypertrophic Cardiomyopathy Treatment

Fineline Cube Oct 16, 2024

CORXEL, formerly known as Ji Xing Pharmaceuticals and Cytokinetics Inc (CYTK, NASDAQ: CYTK) have achieved...

Company Drug

Jiangsu Hengrui’s Hetrombopag Olamine Receives NMPA Review for Severe Aplastic Anemia Indication

Fineline Cube Oct 16, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...

Company Drug

Hinova Pharmaceuticals Gets NMPA Green Light for HP568 Clinical Study in Breast Cancer

Fineline Cube Oct 16, 2024

Hinova Pharmaceuticals Inc. (SHA: 688302), a biotech firm based in Chengdu, has announced that it...

Company Deals

Boehringer Ingelheim Partners with Circle Pharma to Develop First-in-Class Cyclin Inhibitor

Fineline Cube Oct 16, 2024

Boehringer Ingelheim (BI), a leading German pharmaceutical company, has announced a research collaboration and license...

Company Deals

TenNor Therapeutics Secures USD 42.16 Million in Series E Financing for Antibacterial Pipeline

Fineline Cube Oct 16, 2024

TenNor Therapeutics, a clinical-stage pharmaceutical company based in China, has announced the successful completion of...

Company Drug

Huadong Medicine Gets NMPA Green Light for BCMA-Targeted ADC HDM2027 Phase I/IIa Study

Fineline Cube Oct 16, 2024

Huadong Medicine Co., Ltd (SHE: 000963), a Chinese pharmaceutical company, has announced that it has...

Company Medical Device

Lepu Medical Receives Approval for Noninvasive Blood Glucose Meter NeoGlu 01 in China

Fineline Cube Oct 16, 2024

Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003), a leading provider of cardiovascular disease solutions...

Company Drug

Leqembi, Alzheimer’s Drug by Eisai and Biogen, Now Covered by Qihuibao Insurance in China

Fineline Cube Oct 15, 2024

Leqembi (lecanemab), an Alzheimer’s disease treatment co-developed by Eisai Co., Ltd (TYO: 4523) and Biogen...

Company Deals

Bayer AG and Meituan Deepen Partnership to Transform Skin Health Market in China

Fineline Cube Oct 15, 2024

Bayer AG (ETR: BAYN), a leading German multinational pharmaceutical and life sciences company, has expanded...

Company Drug

Changchun High & New Technology Industries Receives FDA Tacit Approval for GenSci122 Clinical Study

Fineline Cube Oct 15, 2024

Changchun High & New Technology Industries (Group) Inc. (SHE: 000661), a leading biopharmaceutical company, has...

Company Drug

Jiangsu Hengrui’s HR19042 Earns Breakthrough Designation for Autoimmune Hepatitis Treatment in China

Fineline Cube Oct 15, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...

Company Drug

Eli Lilly’s Mirikizumab Shows Statistically Significant Improvement in Crohn’s Disease VIVID-1 Study

Fineline Cube Oct 15, 2024

Eli Lilly & Co. (NYSE: LLY), a leading pharmaceutical company in the U.S., has published...

Company Drug

Humanwell Healthcare Secures NMPA Approval for Clinical Trial of HW211026 to Treat Actinic Keratosis

Fineline Cube Oct 15, 2024

Humanwell Healthcare (Group) Co., Ltd (SHA: 600079), a China-based pharmaceutical company, has announced that it...

Company

Thermo Fisher Faces FDA Scrutiny Over Syringe Air Bubble Protocols at North Carolina Plant

Fineline Cube Oct 15, 2024

Thermo Fisher Scientific’s (NYSE: TMO) Greenville, North Carolina, facility has come under scrutiny after a...

Posts pagination

1 … 224 225 226 … 606

Recent updates

  • Hybio Pharmaceutical Licenses Semaglutide to Vitamedic for Brazil Market
  • Merck in Talks to Acquire Revolution Medicines for $28‑32 Billion in Oncology Push
  • Genrix Bio’s GR1803 NDA Accepted for BCMA-Targeted Multiple Myeloma Therapy
  • RemeGen’s RC48 Wins Fourth Breakthrough Therapy Designation for Gastric Cancer Combo
  • Merck Initiates Phase 3 Trial for Calderasib + KEYTRUDA QLEX in KRAS G12C NSCLC
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Hybio Pharmaceutical Licenses Semaglutide to Vitamedic for Brazil Market

Company Deals

Merck in Talks to Acquire Revolution Medicines for $28‑32 Billion in Oncology Push

Company Drug

Genrix Bio’s GR1803 NDA Accepted for BCMA-Targeted Multiple Myeloma Therapy

Company Drug

RemeGen’s RC48 Wins Fourth Breakthrough Therapy Designation for Gastric Cancer Combo

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.